Medical Device and Healthcare Industry Trends — 2026-05-30

Top 5 Headlines Today

• Samsung Electronics — Unveiling AI-powered connected care ecosystem and new Samsung Health features at VivaTech 2026 (June 17–20).

• KOSDAQ Tier System Introduced — Favors medical device companies like Classys; increases burden on biopharmaceutical developers.

• Lunit AI Subscription Business Growth — Cumulative SaaS contracts surpass 930,000; eyeing M&A opportunities in digital pathology.

• FDA Relaxes AI/Wearable Regulations — Lowering market entry barriers for low-risk digital health products.

• Global Diagnostic Imaging Market Boom — Projected to reach USD 74.11B by 2035, growing at a 3.5% CAGR.

Major Company Developments

Samsung Electronics

• What’s Happening: Debuting an AI-powered connected care ecosystem and new Samsung Health features at VivaTech 2026 in Paris (June 17–20), and participating in a panel on the future of AI health experiences.
• Key Stat: VivaTech is Europe’s largest technology exhibition.
• Insight: As Samsung goes all-in on building an AI ecosystem that integrates wearables and healthcare platforms, the market share of Korean manufacturers in the global health-tech sector is visibly expanding. Combined with the FDA's regulatory easing, this opens significant doors for the global competitiveness of Korean firms.

Classys

• What’s Happening: Achieved a 42.7% operating profit margin in Q1 2026, realizing the effects of acquiring Brazilian distributor MedSystems.
• Key Stat: Q1 revenue reached 87.2 billion KRW (+13% YoY); the dip in operating profit was due to one-time accounting adjustments.
• Insight: M&A-driven global supply chain expansion strategies are yielding results and are expected to gain further momentum under the new KOSDAQ Tier System’s premium listing environment.

Lunit

• What’s Happening: Expanding subscription-based AI business in the U.S.; cumulative SaaS contracts exceeded 930,000.
• Key Stat: Seeking market entry opportunities amid active M&A in the global digital pathology sector.
• Insight: In tandem with relaxed FDA regulations for AI medical devices, the overseas revenue momentum for Korean AI diagnostic startups is strengthening. The shift toward a SaaS model is seen as a strategic turning point to lower adoption barriers for medical institutions and secure recurring revenue.

Ministry, Policy, and Regulations

KOSDAQ Tier System Introduced — Benefits Medical Device Firms, Burdens Biotech

• Overview: Splitting KOSDAQ into "Premium" and "Standard" tiers to improve listing and trading environments for medical device firms.
• Impacted Parties: Medical device manufacturers/distributors like Classys (positive); drug development biotech firms (burden).
• Effective Date: Announced May 28, 2026.
• Industry Impact: The medical device sector is well-positioned for the Premium Tier due to high operating margins (42.7%+) and stable cash flow. Conversely, drug developers may face fundraising hurdles in the Standard Tier due to clinical risks and long development timelines.

FDA Eases AI/Wearable Medical Device Regulations

• Overview: Reduced FDA oversight on low-risk digital health products, general wellness devices, and Clinical Decision Support (CDS) software.
• Targets: Samsung Galaxy Watch, Lunit AI diagnostics, wearable biosensors, and other low-risk SaMD.
• Effective Date: Announced January 2026, currently implemented globally.
• Industry Impact: This reduces the time and cost for Korean AI startups to enter the U.S. market and accelerates the commercialization of wearable health features for giants like Samsung and LG.

Digital Health & AI Medicine

• Lunit US SaaS Expansion: Reached 930,000 subscription contracts; market share is growing alongside the M&A trend in digital pathology. FDA easing is expected to accelerate clinical application as evidence data requirements soften.

• Samsung AI Health Ecosystem: Showcasing integrated AI solutions for Samsung Health and wearable devices at VivaTech 2026. Expanding wellness partnerships to enter both healthcare institution and consumer markets.

• FDA TEMPO Pilot Program: Simplifying approval pathways for chronic disease Digital Therapeutics (DTx) through early market entry and risk-based enforcement for digital health developers.

Global MedTech Context

• FDA Low-Risk Digital Health Deregulation (Jan 2026) — Expected to accelerate overseas revenue growth for firms like Lunit and Vuno by shortening U.S. market entry timelines and costs.

• Global Diagnostic Imaging Market Boom (USD 74.11B by 2035, 3.5% CAGR) — Rising export demand for Korean ultrasound/MRI devices from Samsung Medison and Ginos, especially driven by healthcare infrastructure expansion in the Asia-Pacific region.

• Samsung VivaTech 2026 AI Health Showcase — Enhancing trust in Korean wearable and AI healthcare technology, creating opportunities to expand networks with European medical institutions.

Investment, M&A, and Listing Trends

• Classys Acquisition of MedSystems (Brazil): Attained 42.7% Q1 2026 operating margin; a success story for global supply chain expansion strategy.

• Lunit US SaaS Expansion: Surpassed 930,000 cumulative SaaS contracts; actively seeking funding and acquisition opportunities within the digital pathology market.

Today’s Insight

The impact of the FDA’s regulatory easing on the Korean medical device industry will likely unfold in three stages. First, AI diagnostic startups like Lunit and Vuno can accelerate penetration into U.S. hospital networks via the SaaS model. Second, large companies like Samsung and LG can commercialize wearable health features faster, boosting their global competitiveness. Third, the KOSDAQ Tier System will provide a better fundraising environment for medical device firms by placing them in the Premium tier, supporting overseas expansion for SMEs. Ultimately, the combination of deregulation and capital market reform is poised to sharpen the global competitive edge of Korean MedTech.

This Week’s Checkpoints

• VivaTech 2026 (June 17–20, Paris) — Announcements regarding AI health solutions and global partnerships from Samsung, LG, and other Korean health-tech firms.
• FDA TEMPO Pilot Program — Monitoring application deadlines and approval trends (tracking entries of Korean DTx firms).
• KOSDAQ Premium Tier — Analysis of public disclosures and stock market reactions of medical device firms assigned to the Premium tier.

Reader Action Items

• Investors/Executives: Re-evaluate the global competitiveness of Korean medical device stocks following the Samsung VivaTech 2026 presentations and the latest FDA guidelines.
• Startup Leadership: Develop U.S. market entry strategies leveraging FDA low-risk pathways (TEMPO, CDS easing) and review SaaS business models.
• Regulatory/Policy Teams: Review KMFDS innovative medical device designations and KOSDAQ tier listing requirements; strengthen consulting for companies navigating dual-regulatory environments abroad.